CAC2 Childhood Cancer Community News Digest (November 22-28)

Assorted news from last week:

A primer on where the Centers for Medicare and Medicaid Services see Medicaid and the Children’s Health Insurance Program (CHIP) heading in the future. Based on a Health Affairs commentary from Brooks-LaSure and Tsai, the three key priority areas are (1) coverage and access, (2) equity, and (3) innovation and whole-person care.

CAC2 Supporting Organization Oncoheroes Biosciences has been awarded to be part of the 1st generation of companies accelerated in the #BCNHealthBooster, an initiative promoted by the Parc Científic de Barcelona (PCB) of Universitat de Barcelona and BarcelonaCityCouncil, with the collaboration of Barcelona Activa and with the support of Biocat, BioRegion of Catalonia. The project, with an investment of €1 million, was created under the Barcelona Science Plan and is an example of collaboration and consensus among public centres, companies, universities and administrations to promote innovation in health and bring a return on investment in research to society.

A new multi-institution study published in Cancer demonstrates that dexrazoxane, which is administered to pediatric cancer patients to curb the cardiotoxicity of a key chemotherapy drug, has no adverse impacts on these patients, even nearly 20 years later.

Given the number of childhood cancer survivors, the notion that remaining physically active is a key component of all phases of cancer survivorship becomes increasingly salient.

Upcoming Webinars and Online Opportunities:

The Day One Bio Advocacy team will host a Community Meeting on Friday, December 3, 2021 at 11:00 a.m. EST.  During this one-hour Zoom meeting, Day One Co-founder and Chief Medical Officer Dr. Sam Blackman will review the company’s ongoing clinical programs and share insights into our unique approach to pediatric cancer drug development. Please register by following this link.